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Abstract
The success of biomedical researches has led to improvement in human health and increased life expectancy. An
unexpected consequence has been an increase of age-related diseases and, in particular, neurodegenerative
diseases. These disorders are generally late onset and exhibit complex pathologies including memory loss,
cognitive defects, movement disorders and death. Here, it is described as the use of simple animal models such as
worms, fishes, flies, Ascidians and sea urchins, have facilitated the understanding of several biochemical
mechanisms underlying Alzheimer’s disease (AD), one of the most diffuse neurodegenerative pathologies. The
discovery of specific genes and proteins associated with AD, and the development of new technologies for the
production of transgenic animals, has helped researchers to overcome the lack of natural models. Moreover, simple
model systems of AD have been utilized to obtain key information for evaluating potential therapeutic
interventions and for testing efficacy of putative neuroprotective compounds.
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Introduction
Alzheimer’s disease (AD) is the most common form of
dementia. This incurable, degenerative, and terminal dis-
ease is usually diagnosed in people over 65 years of age,
although the less-prevalent early-onset AD can occur
much earlier. The morphologic features observed in AD
patients at autopsy include both extracellular amyloid
deposits as amyloid senile plaques and intracellular neu-
rofibrillary tangles (NFT). The main constituent of the
amyloid deposits is an amphiphilic peptide, derived by
proteolysis from a large membrane spanning precursor
protein, the amyloid precursor protein (APP). According
to the amyloid hypothesis cascade, the beta-amyloid
(Ab) peptide deposits are the fundamental cause of the
disease [1]. Depending on cellular conditions, Ab is mis-
folded and the establishment of Ab conformations,
prone to self-assembling, could represent a key point of
the neurodegenerative process. The intermolecular
aggregation, prompted by instability, strongly correlates
to the increase of ordered structures rich of beta-sheets,
typical of amyloid assemblies. Fibrillar forms of Ab
found in amyloid plaques were previously considered
the major cause of neuronal damage in AD, but recently
it has been discovered that the Ab soluble oligomers,
also known as Ab-derived diffusible ligands (ADDLs),
are the more potent neurotoxins [2]. Another AD hall-
mark are the NFT, composed by neurofilaments and
hyperphosphorylated tau protein, a microtubule asso-
ciated polypeptide. These two markers are common
both to late-onset/sporadic AD and early-onset/familial
AD (FAD) suggesting a common pathogenic pathway
[3]. However, it is not yet well clear, if the presence of
these two hallmarks is the cause or the effect of a cas-
cade of events including oxidative stress, mitochondrial
damage and death for apoptosis. A scheme of these
events is showed in Figure 1.
A model organism is a non-human species that is
extensively studied to understand particular biological
phenomena, with the expectation that discoveries made
in the organism model will provide insight enforceable
for other and more complex organisms. In particular,
model organisms are widely used to explore potential
causes and treatments for human disease when human
experimentation would be unfeasible or unethical. This
strategy is made possible by the common descent of all
living organisms, and the conservation of metabolic and
developmental pathways and genetic material over the
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be informative, but care must be taken when generaliz-
ing from an organism to another one. Moreover, in
developing an animal model system for human disease,
an appropriate model should have a close evolutionary
relationship to humans. Consequently, mice have been
used extensively as AD animal models due to the simi-
larity with the human brain anatomy and the existence
of numerous behavioral tests to examine neural dysfunc-
tion [4]. However, despite the genomic similarities to
humans, mouse and other model organisms typically do
not contract the same genetic diseases, so scientists
must alter their genomes to induce human disease
states. In attempting to engineer a genetic mouse model
for a human disorder, for example, it is important to
know what kind of mutation causes the disease, so that
the same kind of mutation can be introduced into the
corresponding model organism genome. Scientists
approach this task in two main ways: one that is direc-
ted and disease driven, and the other one that is undir-
ected and mutation driven. The undirected mutation-
driven method uses radiation and chemicals to cause
mutations. On the other hand, the directed disease-dri-
ven approach can employ any techniques, depending on
the exact type of mutation involved in the disease under
study. Common directed techniques include transgenesis
or single-gene knock-outs and knock-ins. Transgenic
animals are generated by adding foreign genetic infor-
mation to the nucleus of embryonic cells, thereby inhi-
biting gene expression. This can be achieved by either
injecting the foreign DNA directly into the embryo or
by using a retroviral vector to insert the transgene into
an organism’s DNA. Both knock-out and knock-in mod-
els are ways to target a mutation to a specific gene
locus. These methods are particularly useful if a single
gene is shown to be the primary cause of the disease.
Knock-out mice carry a gene that has been inactivated,
which creates less expression and loss of function;
knock-in mice are produced by inserting a transgene
into an exact location where it is overexpressed.
To generate transgenic mice is not only time-intensive
but also costly. For these reasons, researchers have turned
their attention to invertebrate animal models that have
provided much insight into some of the molecular
mechanisms involved in AD pathogenesis (Table 1). Mod-
eling human disease in simple invertebrate systems is
attractive because genetic screens can be performed in a
relative short time to identify mutations leading to age-
dependent neurodegeneration. Invertebrate models should
give insight into toxic activities of disease-related human
proteins that, in every case, need to be validated in mam-
malian systems. The nematode Caenorhabditis elegans,
the zebrafish Danio rerio, the fruit fly Drosophila melano-
gaster, the Ascidian Ciona intestinalis and the Strongilo-
centrotus purpuratus and Paracentrotus lividus sea
urchins, transgenic or not, can offer many advantages to
obtain new knowledge about the toxic mechanisms under-
lying this human neurodegenerative disease (Figure 2). In
addition, these simple model systems have its genome
completely sequenced and surprisingly, many of the
human disease genes have the counterpart in the genes of
these models. Regardless of their obvious simplicity, these
models allow to identify protein interactions, useful for
understanding the entire regulatory pathways.
Figure 1 The two pathological hallmarks of AD are extracellular plaques and intracellular tangles. Plaques are formed mostly from the
deposition of amyloid beta (Ab) a peptide derived from amyloid precursor protein (APP). The metabolic processing of APP that results in Ab
formation requires two enzymatic cleavage events, a b-secretase cleavage by the aspartyl protease beta-site APP-cleaving enzyme (BACE) and a
g-secretase cleavage dependent on presenilin. Single beta-amyloid peptides, after misfolding, can aggregate and form fibrils and successively
plaques. Filamentous neurofibrillary tangles (NTF) are formed from paired helical filaments composed of hyperphosphorylated tau protein, a
microtubule-associated protein.
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T h en e m a t o d e( r o u n d w o r m )Caenorhabditis elegans (C.
elegans) is a transgenic useful model to study common
and fundamental toxic mechanisms underlying human
neurodegenerative diseases. C. elegans is a free-living
nematode about 1mm in length, which lives in tempe-
rate soil environments. The worm is transparent, thus
facilitating the study of cellular differentiation and other
developmental processes in the intact organism, and
results one of the simplest organisms with a nervous
system [5]. The latter comprises 302 neurons [6,7] and
the neuronal classes include chemosensory, mechano-
sensory and thermosensory. Formation, trafficking, and
release of synaptic vesicles in C. elegans a r eh i g h l yc o n -
served, employing many of the same proteins used in
mammalian neurons.The information available about
this organism has permitted to develop transgenic dis-
ease-associated human protein models [8]. Concerning
neurodegenerative diseases, a relevant advantage of C.
elegans models is its short lifespan, which allows both
rapid construction of different transgenic models and
quick assessment of the experimental interventions. Sev-
eral attempts were done in the past to generate a trans-
genic AD worm based on the increased production of
Ab [9]. Unfortunately, although the C. elegans genome
includes genes encoding proteins related to human APP,
these genes do not possess the region encoding the neu-
rotoxic Ab [10]. So, the generation of an AD model by
mutation of endogenous APP cleavage was ineffective.
However, some researchers developed a transgenic C.
elegans model able to express the human Ab fragment
inside the muscle cells, with a transgene-induced paraly-
sis phenotype [8,11,12]. A construct, called pCL12, con-
taining the chimeric gene unc-54/Ab1-42 was
engineerized. The C. elegans unc-54 gene encodes the
major myosin heavy chain expressed in the body-wall
muscle. Its promoter/enhancer sequences that produce
high-level muscle-specific gene expression were
assembled with a DNA fragment coding for the human
Ab1-42 The minigene was introduced into the nematode
by gonad microinjection to produce Ab constitutively
expressed in the CL2006 strain of C. elegans. The identi-
fication of the transgenic nematodes were done with the
co-injection of pRF4 plasmid which encodes a mutant
collagen gene whose expression leads to an easy recog-
nized Roller phenotype [8]. This mutation causes a roll-
ing movement of the worm instead of the normal
synusoidal one. Using this procedure, it was found that
the amyloid deposits are located intracellularly and the
increased amyloid fibril content in individual worm
from mid-larva to adult stage was caused by an increase
in the deposit size rather than new deposits [12,13].
Table 1 The research application of the most common invertebrate models used for AD
ANIMAL MODEL COMMON NAME RESEARCH APPLICATION
Caenorhabditis elegans Roundworm Localization of amyloid deposit
Effect of aging on the size of amyloid plaques
Ab toxicity and behaviour correlation
Effect of dietary deprivation in AD
Danio rerio Zebrafish Studies on NTF and amyloid plaques
Toxicity of Ab peptide
Mutations in APP, PSEN1 and PSEN2 genes
Drug screening
Drosophila melanogaster Fruit fly Assessment of modulators of BACE1 or APP metabolism
Localization of Ab peptide
Role of tau protein in AD
Ciona intestinalis Ascidian APP processing
Study on familial AD
Drug screening
Paracentrotus lividus Rock sea urchin Relationship between different Ab aggregation forms and toxicity
Different activation of Apoptotic pathways
Sphaerechinus granularis Violet sea urchin Neuroprotective effect of neurotransmitters
Developmental abnormalities due to Ab peptide administration
Figure 2 Simple model systems as zebrafish, Drosophila, C.
elegans, Ascidian and sea urchin have been used to study
neurodegeneration.
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expressing potentially non-amyloid variant forms of Ab
in which single amino acid substitutions (e.g. Leu, Pro)
dramatically reduced or blocked amyloid formation but
it did not reduce toxicity, suggesting that amyloid aggre-
gates itself are not the really toxic species [11]. Trans-
genic C. elegans was also utilized to study the age-
dependence of AD investigating whether in bacterial
deprivation, a form of dietary restriction that extends
lifespan, Ab toxicity can be reduced [14]. Dietary restric-
tion confers a general protective effect against toxicity
and promotes longevity by a mechanism involving heat
shock factor -1 (hsf-1). Moreover, C. elegans model was
also utilized to associate learning and behavior of the
worm with Ab toxicity [14,15]. Many nematodes modify
their behaviors in response to the presence or absence
of food. The Enhanced Slowing Response (ESR), an
experience-dependent learning behavior, relies on a con-
served response to starvation. C. elegans behavior was
investigated after introduction of the human Ab gene in
the nematode, showing decreased lifespan at 23°C, defi-
cits in odorant preference associative learning behavior
and reduced serotonin-stimulated egg laying [16,17].
Danio rerio: from the aquarium to neurodegeneration
studies
The zebrafish is a tropical freshwater and a common
aquarium fish. It is so named for the five uniform, pig-
mented, horizontal blue stripes on the body. External
development and optical clarity during embryogenesis
allows for visual analyses of early developmental pro-
cesses and genetic analyses. As a vertebrate, the basic
organization and divisions of the nervous system are
similar to those of others species, including humans.
The zebrafish CNS contains specialized neuronal popu-
lations of direct relevance for human neurodegenerative
diseases, for example, dopaminergic neurons, cerebellar
Purkinje cells, oligodendrocytes and astrocytes [18-23].
Its anatomic structure and the presence of orthologous
of some human genes [18], permit to use zebrafish as
model for studying neurodegenerative diseases. Through
careful and creative design of screens, indeed, any devel-
opmental or clinically relevant process can be studied,
and zebrafish provides a forward genetic approach for
assigning function to genes, and positioning them in dis-
ease-related pathways. Different techniques were used to
generate transgenic zebrafish with the aim to investigate
about the two hallmarks of AD: NFT and amyloid pla-
ques, starting from microinjection of linearized plasmids
or trasposons, or producing constructs with appropriate
cis-acting regulatory elements [24]. Different transgenic
zebrafish models have been developed and some of
them were used to study tau protein. In AD, tau is
hyperphosphorylated, displaced from its normal
association with microtubules and deposited into NFT.
Since the degree of NFT amount (presence) is closely
correlated with the clinical severity [25,26], tau protein
results to be an important target for research and drug
development. A transgenic model system to study the
functional consequences and trafficking patterns in zeb-
rafish neurons of human tau, either mutated on site
associated with AD or altered at selected post-transla-
tional modification sites, has been developed. This
model produced a cytoskeleton disruption resembling
the NTF in human disease and it could be potentially
utilized to dissect a hierarchy of mechanisms in AD.
To the purpose of constructing models for investigat-
ing Ab toxicity, several approaches have been done.
Simple incubation of zebrafish embryos in media con-
taining Ab peptide appears to produce effects on their
neural development as monitored by changes in the pat-
terns of neurons if compared with non-transgenic zebra-
fish. Moreover, Ab can also induce cell- and embryo-
degeneration [27]. It has also been generated a trans-
genic zebrafish model to facilitate screening for drugs
suppressing Ab toxicity, by expressing the human Ab 42
amino acid residue form of in the melanophores (corre-
sponding to human melanocytes) constituting the zebra-
fish’s dark surface stripes. The hope was to create a
highly visible and, at the same time, viable and fertile
phenotype zebrafish larvae. The larvae should then be
arrayed in microtiter plates to screen compound
libraries for drug acting to reduce Ab toxicity. To this
aim it was used a DNA fragment from the promoter of
the microphthalmia-associated transcription factor
(mitfa) a crucial gene for melanocyte differentiation in
zebrafish [28]. This was coupled to DNA encoding for a
secretory signal fused to Ab Unfortunately, fish bearing
this transgene only showed an aberrant pigment pheno-
type at the advanced age of 16 months, too late for the
use in drug screening [29]. Nevertheless, the alteration
of the zebrafish pigment pattern could be useful to ana-
lyzing the toxic peptide action [29]. Mutations in three
genes are known to cause familial AD (FAD). The muta-
tions occur in the genes encoding the APP and preseni-
lin 1 (PSEN1) and 2 (PSEN2) and cause the increased
secretion of the pathological Ab transgenic zebrafish
was engineered to analyze presenilin function in the
hope to understand the role of mutations of its human
orthologous in AD.
Zebrafish PSEN1 sequence and activity were pre-
viously analysed and conservation of protein primary
structure was noted [30]. Gene transcripts were appar-
ently present in all cells at all examined developmental
stages. When zebrafish PSEN1 protein expression was
driven at high levels in cultured human HEK293 cells,
the zebrafish protein displaced human PSEN1 from g-
secretase complexes, indicating sufficient structural
Di Carlo Immunity & Ageing 2012, 9:3
http://www.immunityageing.com/content/9/1/3
Page 4 of 8conservation to interact with other complex compo-
nents. Moreover, zebrafish PSEN1 possesses sufficient
primary structural differences from human PSEN1
because its proteolitic action mainly produces the Ab40
form. Moreover, it has also been demonstrated that
mutation of one of the two critical catalytic aspartate
residues in zebrafish PSEN1 could abolish its g-secretase
activity [30].
A fly in the forefront of AD research
The Drosophila melanogaster is a small, common fly
findable near unripe and rotten fruit. Wildtype fruit flies
have brick red eyes, are yellow-brown in color, and have
transverse black rings across their abdomen and exhibit
sexual dimorphism. Thomas Hunt Morgan was the pio-
neer biologist in Drosophila studies in the early 1900’s,
discovering sex linkage and genetic recombination,
which placed the small fly in the forefront of genetic
research. More recently the biological similarities
between human and Drosophila genes have permitted to
utilize the fly to exploit the field of neurodegenerative
diseases, with a great success [31]. The fly has a brain,
containing approximately 200,000 neurons, and like the
vertebrate central nervous system, it is composed of a
series of functionally specialized substructures as sources
of sensory input such as optic and olfactory. The neu-
rons are very similar to their human equivalents in
terms of shape, synaptic intercommunications and bio-
chemical signatures. These functional and structural
similarities allow constructing fly models of human dis-
eases. These models typically involve transgenic fly
expressing a human gene bearing a known dominant
mutation or expressing a targeted loss-of-function muta-
tion generated in fly orthologous of these genes [32-38].
Fly models of AD are also available to the community
and are now providing new insights into disease
mechanisms and assisting in the identification of novel
targets for therapy [33]. A particular model of Ab toxi-
city has been achieved by creating transgenic flies carry-
ing gal4-driven constructs encoding human APP and
human beta-site APP-cleaving enzyme 1 (BACE1) able
to generate the Ab peptide [39]. gal4/upstream activat-
ing sequence (UAS) system is usefully used in D. mela-
nogaster, to achieve tissue-specific transgene expression
[40]. In this system, the yeast GAL4 protein is expressed
in particular cells by using selected enhancers or promo-
ters. GAL4 activates a chosen gene upon binding to the
UAS. This Ab toxicity relatively complex model is ideal
for the assessment of modulators of BACE1 or APP
metabolism, but, in some aspects, is less easy to handle
than the models in which the Ab sequence is fused
downstream of a secretion signal peptide [41-43]. In
these latter models, the expressed Ab peptide is in part
released in the extracellular environment. Another
fraction, instead, is accumulated intracellularly and can
be correlated with early phenotypes such as locomotor
dysfunction and severity. Moreover, immunogold elec-
tron microscopy reveals that the Ab peptides localize in
the endoplasmic reticulum (ER), Golgi appartus and
lysosomes, but not in the nucleus or mitochondria [44].
This finding suggested that the potentially reversible
early phenotypes in AD could be mediated by the intra-
cellular accumulation and aggregation of Ab. Although
studies on Ab can help to understand one crucial aspect
of AD pathogenesis, the investigation on the role of tau
is also of great importance [45,46]. Fly tau-overexpres-
sion models have allowed to investigate the role of tau
in AD. Although wild type human tau is neurotoxic
when overexpressed in neuronal tissues, the rough eye
and longevity phenotypes in Drosophila model systems
are more severe when AD related variants of tau are
expressed [47], even when tau d o e sn o tf o r mn e u r o f i -
brillary tangles [48]. Moreover, flies overexpressing wild-
type human tau can be induced to form intracellular
inclusions resembling neurofibrillary tangles, when gly-
cogen synthase kinase 3b (GSK3b) activity is increased
[49]. This finding is in agreement with the known
human pathways of tau toxicity that seems to require
hyperphosphorylation of tau to speed up the aggrega-
tion process. Thus, Drosophila models have permitted
to obtain new information about the mechanism of the
two principal AD hallmarks.
Ascidian: an urochordata sister of vertebrate.
Ascidian is an urochordata (sea squirt), a tunicate
widely distributed in different seas. Ciona intestinalis is
a solitary tunicate with a cylindrical, gelatinous body, up
to 14 cm long, covered by a tunic, made of the polysac-
charide tunicin. One of the ends of the body is always
fixed to rock, coral or solid surfaces. The other end,
opposite to the part secured to the substratum, has two
openings, the buccal and atrial siphons. Ciona intestina-
lis has attracted the interest of biologists for develop-
mental studies and its mitochondrial and nuclear
genomes have been sequenced [50]. Because of their dis-
tant evolutionary relationship to vertebrates, it can be
difficult to extrapolate findings obtained in non-chor-
date invertebrates to study human neurological diseases.
In contrast to other invertebrate models, Ascidians, like
humans, are chordates, share a larval notochord, and
undergo neurulation to form a dorsal hollow neural
tube. Thus, they can be considered the true sister group
of vertebrates and provide an excellent genomic back-
ground for modeling human diseases [51]. Ascidians
have a peripheral nervous systems composed of approxi-
mately 350 neuronal cells, including an anterior sensory
vesicle and a visceral ganglion containing moto-neurons.
This simple chordate nervous system is important in
coordinating several aspects of the tadpole behavior,
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to the environmental cues, necessary for settlement [52].
To determine whether the ascidian Ciona intestinalis
could be used as a model for AD, transgenic larvae were
g e n e r a t e de x p r e s s i n gw i l dt y p ea n dm u t a n tf o r m so f
human APP (hAPP695). Expression of hAPP695 appears
to be processed in a similar way to the well-character-
ized Ab cascade. Furthermore, Ab f o r m sd e p o s i t sa s
assessed by thioflavin S, a dye commonly used for stain-
ing amyloid plaques [53]. Increased plaques formation
can be achieved by introducing point mutations asso-
ciated with familial AD into hAPP695. Transgenic Asci-
dians expressing Ab1-42 in the larval nervous system
display severe deficiencies with their ability to fixing up,
a behavioral response that is important for metamor-
phosis. Moreover, treatment of transgenic larvae with 3-
amino-1-propanesulfonic acid (3-APS), an anti-amyloid
therapeutic drug, leads both to a decrease in plaque for-
mations, in a dose-dependent manner, and an improve-
ment in larval attachment. Practically, this AD Ascidian
model can be employed to identify factors modulating
amyloid deposition, the associated disruption of normal
cellular function and behaviors [54].
Sea urchin a model system to correlate different Ab
aggregates and toxicity
Sea urchin is a useful model system for studying pro-
blems in early animal development, and more recently
it has been used for identifying specific pathways
involved in human pathology or as an indicative tool
for pharmacological evaluation. Historically, sea urchin
has been a key system in elucidating a variety of classic
developmental problems and the regulation of early
embryo differentiation [55]. Moreover, sea urchin
occupies a key phylogenetic position because it is the
only nonchordate belonging to Deuterostomes and the
results obtained on this embryo can be extrapolated
and compared to those of higher eukaryotes such as
mammalians. Nervous systems begin to be present
with some neurons and neurites in the structure called
ciliary band, in the esophagus and intestine [56]. All
the morphological and biochemical events that appear
perfectly synchronous in the sea urchin embryo cul-
tures are perturbed when they are exposed to toxic
agents of different nature such as metals or teratogens
and neurotoxicants and their adverse effects produce
uniform phenotypes for a given toxicant and critical
exposure period [57]. Furthermore, several clusters of
neurons with associated neuropil are organized in
ganglia, the largest of which is the apical organ of the
larva, composed of 4-6 bilaterally positioned sensory
cells containing serotonin. Moreover, Strongylocentro-
tus purpuratus sea urchin genome has been sequenced
and despite having no eyes, nose, or ears, has genes
involved in vision, hearing and smell in the humans
[58]. Moreover, mechanisms that are involved in nor-
mal or altered cell homeostasis common to humans
have been identified; apoptosis, for example, a mechan-
ism at the basis of neurodegeneration, is well con-
served and studied in sea urchin [59,60]. Paracentrotus
lividus sea urchin embryo has permitted to study the
structure-activity relationship between different Ab
aggregation forms and toxicity [61]. Using a recombi-
nant Ab42 (rAb42), a preliminary biophysical work has
been done to produce rAb42 different aggregation
forms. Small oligomers were obtained at physiological
pH, instead larger aggregates at low pH; their size was
verified by dynamic light scattering measurements.
When sea urchin cultures were incubated with the two
different Ab aggregation species, it was observed that
Ab oligomeric forms significantly increased the level of
toxicity with respect to the larger aggregate forms,
indicating that the state of Ab assembly appears to
influence their biological activities.
An antigen related to the human APP, called PlAPP
was identified in sea urchin embryo [62]. PlAPP, as in
humans, is processed producing a polypeptide of about
10 kDa, suggesting that some molecules and pathways
involved in the degenerative process could be conserved
during evolution. Using sea urchin it has been possible
to find a correlation between Ab aggregation forms and
different apoptotic pathway activations [63]. Ab aggre-
gates, indeed, induce apoptosis by extrinsic pathway
activation, whereas oligomers induce apoptosis both by
extrinsic and intrinsic pathway activation. The involve-
ment of mitochondria, pivotal organelles in controlling
cell life and death, can explain the major toxicity of oli-
gomers if compared to larger aggregates [63].
Using Sphaerechinus granularis,a n o t h e rs e au r c h i n
species, it was examined the critical periods in which
different types of anomalies are evoked by Ab and,
importantly, established the role played by acetylcholine
(ACh) and other neurotransmitters such as serotonin
(5HT) and cannabinoids as potential protectants [64].
These morphological studies allow determining the bio-
chemical and molecular mechanisms involved both in
the damage caused by the amyloid structures and in the
protection provided by the neurotransmitters.
Sphaerechinus granularis embryo was also employed
to compare developmental abnormalities caused by
administration of exogenous APP96-110 and Ab or dif-
ferent compounds [65]. Although both peptides elicited
dysmorphogenesis, Ab was far more potent; in addition,
whereas Ab produced abnormalities at developmental
stages ranging from early cleavage divisions to the late
pluteus, APP96-110 effects were restricted to the inter-
mediate, mid-blastula, stage. For both agents, anomalies
were prevented or reduced by addition of lipid-
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nabinoids; physostigmine, a carbamate-derived cholines-
terase inhibitor, was also effective. In contrast, agents
acting on NMDA receptors (memantine) or a-adrener-
gic receptors (nicergoline), therapeutic in AD, were
themselves embryotoxic, as was tacrine, a cholinesterase
inhibitor belonging to a chemical class different from
physostigmine. Agents acting downstream from recep-
tor-mediated events also provided protection: both the
increase of cyclic AMP with caffeine or isobutylmethyl-
xanthine or the administration of the antioxidant a-
tocopherol, are all partially effective.
Conclusions
C. elegans, zebrafish, Drosophila, Ascidian,s e au r c h i n ,
together with other non human model systems no dis-
cussed here, summarize some features of AD disease.
They have been and will be useful to elucidate mechan-
istic details and provide the basis for evaluating drug
therapies. The simple model systems could allow asses-
sing the pathological importance of a large number of
possible modifier genes particularly where orthologous
exist. Genes that are found to have a functional impor-
tance in simple model systems, as well as showing link-
age to AD in humans, will be of particular interest for
future detailed studies. Moreover, fundamentally impor-
tant gene products will be the targets for a new genera-
tion of therapeutic compounds for the treatment, or
even prevention, of AD. Genetic screens, indeed, can
help to define new neuroprotective pathways.
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